Skip to main content

Advertisement

Log in

Cutaneous and visceral leishmaniasis during anti-TNFα therapy

  • main topic
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

The long-term use of novel antipsoriatic systemic biotechnological drugs may increase susceptibility to opportunistic infections. Several cases of visceral leishmaniasis have been reported in immunosuppressed individuals, including those who have been treated with tumour necrosis factor alpha (TNFα) blocking agents. Simultaneous occurrence of cutaneous and visceral involvement has been more rarely recorded in the medical literature. Herein, we describe a case of mucosal leishmaniasis occurring in a farmer living in an endemic region, who was treated with golimumab because of psoriatic arthritis. This highlights the importance of recognizing cutaneous lesions as a first indicator of possible underlying kala-azar disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Guarneri C, Tchernev G, Bevelacqua V, Lotti T, Nunnari G. The unwelcome trio: HIV plus cutaneous and visceral leishmaniasis. Dermatol Ther. 2016;29(2):88–91.

    Article  CAS  PubMed  Google Scholar 

  2. Guarneri C, Vaccaro M, Cannavò SP, Borgia F, Guarneri B. Erythematous-edematous-infiltrative plaque on the face: cutaneous angio-lupoid leishmaniasis. Eur J Dermatol. 2002;12(6):597–9.

    PubMed  Google Scholar 

  3. Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, Gualdi G, Guarneri C, Borsari S, Cassano N. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7.

    Article  PubMed  Google Scholar 

  4. Ali T, Bronze MS, Kaitha S, Mahmood S, Ftaisi A, Stone J. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79–99.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Amerio P, Amoruso G, Bardazzi F, Campanati A, Cassano N, Conti A, Gisondi P, Guarneri C, Mazzotta A, Piaserico S, Prestinari F, Prignano F, Zane C, de Simone C. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. J Dermatolog Treat. 2013;24(4):305–11.

    Article  CAS  PubMed  Google Scholar 

  6. Guarneri C, Guarneri F. Symmetrical cutaneous leishmaniasis. Acta Derm Venereol. 2005;85(3):281–2.

    PubMed  Google Scholar 

  7. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27:305–18.

    Article  CAS  PubMed  Google Scholar 

  8. Alvar J, Velez ID, Bern C, Herrero M, Desieux P. WHO Leishmaniasis Control Team: leishmaniasis worldwide and global estimates of its incidence. PLOS ONE. 2012;7:e35671.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Monge-Maillo B, Norman FF, Cruz I, Alvar J, López-Vélez R. Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLOS Negl Trop Dis. 2014;8(8):e3021.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Borgia F, Vaccaro M, Guarneri F, Manfrè C, Cannavò SP, Guarneri C. Mucosal leishmaniasis occurring in a renal transplant recipient. Dermatology (Basel). 2001;202(3):266–7.

    Article  CAS  Google Scholar 

  11. Celesia BM, Cacopardo B, Massimino D, Gussio M, Tosto S, Nunnari G, Pinzone MR. Atypical presentation of PKDL due to leishmania infantum in an HIV-infected patient with relapsing visceral leishmaniasis. Case Rep Infect Dis. 2014;2014:370286.

    PubMed  PubMed Central  Google Scholar 

  12. Català A, Roè E, Dalmau J, Pomar V, Munoz C, Yelamos O, Puig L. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology (Basel). 2015;230:204–7.

    Article  Google Scholar 

  13. Vaccaro M, Magaudda L, Cutroneo G, Trimarchi F, Barbuzza O, Guarneri F, Guarneri B. Changes in the distribution of laminin α1 chain in psoriatic skin: immunohistochemical study using confocal laser scanning microscopy. Br J Dermatol. 2002;146(3):392–8.

    Article  CAS  PubMed  Google Scholar 

  14. Guarneri F, Guarneri C, Guarneri B. Biologic agents in the treatment of psoriasis. Recent Pat Inflamm Allergy Drug Discov. 2007;1(3):193–217.

    Article  CAS  PubMed  Google Scholar 

  15. Gisondi P, Amerio P, Amoroso GF, Antonucci VA, Bardazzi F, Buongiorno MR, Bruni P, Campanati A, Caproni M, Carlesimo M, Carrera CG, Cianchino G, Cimmino G, Costanzo A, Cozzani E, Dapavo P, D’amico D, De Simone C, Del Giglio M, Di Nuzzo S, Gai F, Galluccio AG, Goffredo A, Gualdi G, Guarneri C, Kokelj F, Lasagni C, Loconsole F, Longo V, Malagoli P, Miracapillo A, Mugheddu C, Parodi A, Pellegrino M, Peserico A, Piaserico S, Pistone G, Potenza C, Plumari A, Stingeni L, Strippoli D, Travaglino M, Girolomoni G. Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. G Ital Dermatol Venereol. 2013;148(6 Suppl 1):1–10.

    CAS  PubMed  Google Scholar 

  16. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47–57.

    Article  CAS  PubMed  Google Scholar 

  17. Tchernev G, Guarneri C, Bevelacqua V, Wollina U. Carcinoma cuniculatum in course of etanercept: blocking autoimmunity but propagation of carcinogenesis? Int J Immunopathol Pharmacol. 2014;27(2):261–6.

    Article  CAS  PubMed  Google Scholar 

  18. Cintolo M, Guarneri C, Lentini M. A case of molluscum contagiosum infection in a patient with Crohn’s disease, receiving combination therapy with azathioprine and adalimumab. J Crohns Colitis. 2015;9(7):593–4.

    Article  PubMed  Google Scholar 

  19. Guarneri C, Wollina U, Chokoeva A, Lotti TM, Tchernev G. A strange infiltrative plaque on the face. Braz J Infect Dis. 2016;20(2):214–5.

    Article  PubMed  Google Scholar 

  20. Postigo C, Llamas R, Zarco C, Rubio R, Pulido F, Costa JR, Iglesias L. Cutaneous lesions in patients with visceral leishmaniasis. J Infect. 1997;35:265–8.

    Article  CAS  PubMed  Google Scholar 

  21. Donati P, Paolino G, Panetta C, Muscardin L, Cota C, Giuliani M. Visceral leishmaniasis revealed by a squamous cell carcinoma in an HIV-1 infected patient. Infection. 2013;41:575–8.

    Article  CAS  PubMed  Google Scholar 

  22. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter HR, López-Vélez R, Moreno J. The relationship betweeen leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Colebunders R, Depraetere K, Verstraeten T, Lambert J, Hauben E, Van Marck E, Maurer T, Banuls AL, Dujardin JC. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol. 1999;41:847–50.

    Article  CAS  PubMed  Google Scholar 

  24. Van Grinsven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012;26:309–22.

    Article  Google Scholar 

  25. De Simone C, Amerio P, Amoruso G, Bardazzi F, Campanati A, Conti A, Gisondi P, Gualdi G, Guarneri C, Leoni L, Loconsole F, Mazzotta A, Musumeci ML, Piaserico S, Potenza C, Prestinari F. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673–82.

    Article  PubMed  Google Scholar 

  26. Bardazzi F, Amerio P, Amoruso G, Campanati A, Conti A, De Simone C, Gisondi P, Gualdi G, Guarneri C, Loconsole F, Mazzotta A, Musumeci ML, Odorici G, Piaserico S, Potenza C, Scudeller L, Alphard Study Group. Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. Eur Rev Med Pharmacol Sci. 2014;18(22):3435–52.

    CAS  PubMed  Google Scholar 

  27. Tchernev G, Lotti T, Cardoso JC, Kanazawa N, Guarneri C, Wollina U. Cancer, infection and disturbances of the integrity of tissue homeostasis: the most significant triggers for molecular mimicry and autoimmunity in dermatology? Wien Med Wochenschr. 2014;164(13–14):245–6.

    Article  PubMed  Google Scholar 

  28. Guarneri C, Guarneri F, Risitano G, Lentini M, Vaccaro M. Solitary asymptomatic nodule of the great toe. Int J Dermatol. 2005;44(3):245–7.

    Article  PubMed  Google Scholar 

  29. Borgia F, Guarneri C, Guarneri F, Vaccaro M. Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug? Br J Dermatol. 2005;153(3):674–5.

    Article  CAS  PubMed  Google Scholar 

  30. Guarneri C, Cannavò SP. Dermacase. Can you identify this condition? Sarcoidosis. Can Fam Physician. 2012;58(8):859–61.

    PubMed  PubMed Central  Google Scholar 

  31. Cannavò SP, Lentini M, Magliolo E, Guarneri C. Cutaneous angiosarcoma of the face. J Eur Acad Dermatol Venereol. 2003;17(5):594–5.

    Article  PubMed  Google Scholar 

  32. Antinori S, Calattini S, Longhi E, Bestetti G, Piolini R, Magni C, Orlando G, Gramiccia M, Acquaviva V, Foschi A, Corvasce S, Colomba C, Titone L, Parravicini C, Cascio A, Corbellino M. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8‑year experience in Italy and review of the literature. Clin Infect Dis. 2007;44:1602–10.

    Article  CAS  PubMed  Google Scholar 

  33. Khan A, Coakley G, Cosgrove C, Lockwood D. Let off the leash: kala-azar following the use of tumour necrosis factor antibodies. BMJ Case Rep. 2010; doi:10.1136/bcr.04.2010.2878.

    Google Scholar 

  34. Di Masi F, Ursini T, Iannece MD, Chianura L, Baldasso F, Foti G, Di Gregorio P, Casabianca A, Storaci N, Nigro L, Colomba C, Marazzi MG, Todaro G, Tordini G, Zanelli G, Cenderello G, Acone N, Polilli E, Migliore S, Almi P, Pizzigallo E, Sagnelli E, Mazzotta F, Russo R, Manzoli L, Parruti G. Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment. Antimicrob Agents Chemother. 2014;58(1):414–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. WHO. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva: WHO; 2010. 22–26 March 2010.

    Google Scholar 

  36. Allenbach C, Launois P, Mueller C, Tacchini-Cottier F. An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection. Eur J Immunol. 2008;38:720–31.

    Article  CAS  PubMed  Google Scholar 

  37. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, Maverakis E. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol. 2013 Apr;44(2):121–40. doi:10.1007/s12016-012-8301-7. Review.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Georgi Tchernev.

Ethics declarations

Conflict of interest

C. Guarneri, V. Bevelacqua, J. W. Patterson, and G. Tchernev declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guarneri, C., Bevelacqua, V., Patterson, J.W. et al. Cutaneous and visceral leishmaniasis during anti-TNFα therapy. Wien Med Wochenschr 167, 78–82 (2017). https://doi.org/10.1007/s10354-016-0527-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-016-0527-1

Keywords

Navigation